Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of 4.32% and Operating profit at 2.92% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 7.81% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of 4.32% and Operating profit at 2.92% over the last 5 years
3
With a fall in Net Sales of -8.59%, the company declared Very Negative results in Mar 25
Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,851 Million (Small Cap)
23.00
NA
1.57%
0.54
5.94%
1.36
Revenue and Profits:
Net Sales:
1,077 Million
(Quarterly Results - Jun 2025)
Net Profit:
38 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
12.58%
0%
12.58%
6 Months
1.04%
0%
1.04%
1 Year
21.21%
0%
21.21%
2 Years
-1.24%
0%
-1.24%
3 Years
13.88%
0%
13.88%
4 Years
6.01%
0%
6.01%
5 Years
24.44%
0%
24.44%
Anhui Fengyuan Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.32%
EBIT Growth (5y)
2.92%
EBIT to Interest (avg)
4.90
Debt to EBITDA (avg)
2.86
Net Debt to Equity (avg)
0.54
Sales to Capital Employed (avg)
1.38
Tax Ratio
20.12%
Dividend Payout Ratio
28.89%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.31%
ROE (avg)
7.81%
Valuation key factors
Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
1.36
EV to EBIT
31.56
EV to EBITDA
14.27
EV to Capital Employed
1.23
EV to Sales
1.00
PEG Ratio
NA
Dividend Yield
1.57%
ROCE (Latest)
3.91%
ROE (Latest)
5.94%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
1,077.40
1,178.70
-8.59%
Operating Profit (PBDIT) excl Other Income
80.30
98.50
-18.48%
Interest
7.80
8.10
-3.70%
Exceptional Items
3.60
-7.70
146.75%
Consolidate Net Profit
37.70
52.40
-28.05%
Operating Profit Margin (Excl OI)
37.20%
54.00%
-1.68%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -8.59% vs 10.20% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -28.05% vs -7.42% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
4,250.70
4,237.90
0.30%
Operating Profit (PBDIT) excl Other Income
323.00
338.60
-4.61%
Interest
31.30
34.60
-9.54%
Exceptional Items
-5.30
-6.90
23.19%
Consolidate Net Profit
157.70
157.30
0.25%
Operating Profit Margin (Excl OI)
42.50%
47.10%
-0.46%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.30% vs 6.72% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 0.25% vs 4.24% in Dec 2023
About Anhui Fengyuan Pharmaceutical Co., Ltd. 
Anhui Fengyuan Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






